| Gender (% male) | 31% (12) |
| Known CAD | 56% (22) |
| Pulmonary Hypertension | 51% (20) |
| Atherosclerosis Risk Factors |
| Tobacco Use (prior or current) | 46% (18) |
| Hypertension | 67% (26) |
| Hyperlipidemia | 54% (21) |
| Diabetes mellitus | 18% (7) |
| Medication Regimen |
| ACE Inhibitors or ARB | 51% (20) |
| Beta-Blockers | 72% (28) |
| Aspirin | 74% (29) |
| Statin | 69% (27) |
| Diuretic | 46% (18) |
| Cardiac Structure/Function |
| LVEF (%) | 49 ± 14% |
| LV Dysfunction (EF < 50%) | 49% (19) |
| LV End-Diastolic Volume | 186 ± 57 ml |
| LV End-Systolic Volume | 106 ± 56 ml |
| RV EF (%) | 51 ± 11% |
| RV Dysfunction (EF < 50%) | 31% (12) |
| RV End-Diastolic Volume | 169 ± 62 ml |
| RV End-Systolic Volume | 96 ± 52 ml |
